Recurrence of Non-functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burden-Based Prediction Model

2021 ◽  
Author(s):  
Ding-Hui Dong ◽  
Xu-Feng Zhang ◽  
Alexandra G. Lopez-Aguiar ◽  
George Poultsides ◽  
Flavio Rocha ◽  
...  
Keyword(s):  
Prediction Model ◽  
Neuroendocrine Tumors ◽  
Curative Resection ◽  
Tumor Burden ◽  
Pancreatic Neuroendocrine Tumors

scholarly journals Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection

HPB ◽  
2020 ◽  
Vol 22 (8) ◽  
pp. 1149-1157 ◽  
Author(s):  
Ding-Hui Dong ◽  
Xu-Feng Zhang ◽  
Alexandra G. Lopez-Aguiar ◽  
George Poultsides ◽  
Eleftherios Makris ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Tumor Recurrence ◽  
Curative Resection ◽  
Tumor Burden ◽  
Pancreatic Neuroendocrine Tumors

MRI-based nomogram estimates the risk of recurrence of primary nonmetastatic pancreatic neuroendocrine tumors after curative resection

2018 ◽  
Vol 50 (2) ◽  
pp. 397-409 ◽  
Author(s):  
Hai-Tao Sun ◽  
Shi-Long Zhang ◽  
Kai Liu ◽  
Jian-Jun Zhou ◽  
Xing-Xing Wang ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Curative Resection ◽  
Pancreatic Neuroendocrine Tumors ◽  
Risk Of Recurrence

scholarly journals Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Bo Zhou ◽  
Canyang Zhan ◽  
Jie Xiang ◽  
Yuan Ding ◽  
Sheng Yan
Keyword(s):  
Pancreatic Duct ◽  
Neuroendocrine Tumors ◽  
Main Pancreatic Duct ◽  
Curative Resection ◽  
Who Classification ◽  
Prognostic Significance ◽  
Small Sample ◽  
Neutrophil To Lymphocyte Ratio ◽  
Pancreatic Neuroendocrine Tumors ◽  
Lymphocyte Ratio

Abstract Background The present study aimed to investigate the prognostic significance of preoperative main pancreatic duct dilation and the neutrophil-to-lymphocyte ratio (PD-NLR) in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection. Methods Sixty-four consecutive PNETs of the head that underwent curative resection were included in the study. Preoperative main pancreatic duct dilation (PD) was defined as a pancreatic duct dilation greater than 3 mm before surgery. Patients with both PD and an elevated NLR (> 3.13), with PD or elevated NLR, or neither of these characteristics were allocated a PD-NLR score of 2, 1, or 0, respectively. Univariate, multivariate and Kaplan-Meier analyses were used to calculate overall survival (OS) and disease-free survival (DFS). Results Preoperative PD-NLR score was correlated with tumor size (P = 0.005), T-stage (P = 0.016), lymph node metastasis (P <  0.001), distant metastasis (P = 0.005), type of hormone production (P = 0.006), perineural invasion (P = 0.014), and WHO classification (P <  0.001). Patients with a high PD-NLR score had a significantly poor OS and DFS relative to those with a low PD-NLR score (P <  0.001). In the multivariate analysis, PD-NLR score was an independent predictor of OS and DFS for PNET of the head (both P <  0.05). In the analyses of the various subgroups, preoperative PD-NLR score was also a predictor of OS and DFS. Additionally, the survival predictive capability of PD-NLR score was superior to that of WHO classification. Conclusions Despite the retrospective nature and small sample size of the present study, the results suggest that preoperative PD-NLR score can serve as an independent prognostic marker of early survival in patients with PNETs of the head undergoing curative resection. Further large prospective studies are necessary to validate our findings.

scholarly journals Treatment Options for Pancreatic Neuroendocrine Tumors

Cancers ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 828 ◽  
Author(s):  
Amit Akirov ◽  
Vincent Larouche ◽  
Sameerah Alshehri ◽  
Sylvia L. Asa ◽  
Shereen Ezzat
Keyword(s):  
Neuroendocrine Tumors ◽  
Treatment Options ◽  
Distant Metastases ◽  
Mass Effect ◽  
Tumor Burden ◽  
Management Approach ◽  
Pancreatic Neuroendocrine Tumors ◽  
Genetic Syndromes ◽  
Stratification System ◽  
Specific Symptoms

The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these factors may assist in forming a risk stratification system permitting a tailored management approach. Most PanNETs are classified as non-functional because they are not associated with clinical sequelae of hormone excess. They are characterized by non-specific symptoms, such as abdominal pain or weight loss, resulting from mass effect related to the pancreatic tumor or secondary to distant metastases. Accurate staging of the disease is essential for determining the appropriate approach to therapy. As cure is only potentially possible with surgical resection of the tumor, it is recommended to remove all localized and limited metastatic disease. However, many patients present with metastatic and/or advanced local disease. In such instances, the goal of therapy is to control tumor growth and/or decrease tumor burden, lengthen survival, and palliate local symptoms and those of hormone excess. This typically requires a multimodal approach, including surgery, liver-directed treatment, and systemic medical therapy.

Nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e15654-e15654
Author(s):  
Cansu Guney Genc ◽  
Stefano Partelli ◽  
Massimo Falconi ◽  
Francesca Muffatti ◽  
Susan van Dieren ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Curative Resection ◽  
Pancreatic Neuroendocrine Tumors

Tumor burden in serotonin secreting pancreatic neuroendocrine tumors after initiating telotristat ethyl.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 367-367
Author(s):  
Susan Giacalone ◽  
Valentina Di Gialleonardo ◽  
Kris Murali ◽  
Vijay N. Joish
Keyword(s):  
Neuroendocrine Tumors ◽  
Clinical Laboratory ◽  
Data Extraction ◽  
Tumor Burden ◽  
Low Grade ◽  
Pancreatic Neuroendocrine Tumors ◽  
Radiological Data ◽  
Before And After ◽  
Well Differentiated ◽  
Practice Methods

367 Background: Pancreatic neuroendocrine tumors (pNETs) characterized by high serotonin levels and carcinoid syndrome (CS) are rare. We evaluated tumor burden in a subgroup of patients with pNETS from the real-world TELEACE study before and after initiating telotristat ethyl (TE) in US clinical practice. Methods: Detailed methods of the TELEACE study have been reported previously. This was a retrospective, single arm, pre-post physician panel-based chart review of patients who received TE for at least 6 months. Descriptive statistics analyzed demographic, clinical, laboratory and radiological data extracted from medical charts of TELEACE patients with pNETS. Results: Fifty-two patients with pNETS initiating TE were eligible for this analysis. The average age at the time of TE initiation was 60+10.4 years; 64% were males. The majority of patients had well-differentiated (60%) tumors and low-grade (54%) tumor status. Patients received TE for an average of 11.5+7.84 months, and 21% were still receiving TE at the time of data extraction. Diarrhea and flushing were the most common CS symptoms recorded at the time of TE initiation. Urinary 5-HIAA levels were reported for 9 patients before and for 2 patients after TE initiation. Mean (median) 5-HIAA levels before and after TE initiation were 693 (211) and 22 (22) µmol/24h, respectively. Significant mean reduction in tumor size of 0.67 cm after TE initiation (P = 0.017) was observed. Conclusions: This subgroup analysis of the TELEACE study population showed that the addition of TE to somatostatin analog treatment may positively impact tumor burden for patients with functional pNETs.

Sign in / Sign up

Export Citation Format

Share Document